Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
This antagonism results in increased p53 activity and can also re-activates the p53 pathway and resensitize the glioblastoma cells to apoptosis.
|
30656973 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Impairment of IMPDH2 activity triggers nucleolar stress and growth arrest of glioblastoma cells even in the absence of functional p53.
|
31371825 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Alkylaminophenol Induces G1/S Phase Cell Cycle Arrest in Glioblastoma Cells Through p53 and Cyclin-Dependent Kinase Signaling Pathway.
|
31001122 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma.
|
30940658 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Quantitative morphological tumor characteristics on post-contrast T1-weighted MRI can to a certain degree provide insights regarding Ki67 and p53 status in patients with glioblastoma.
|
31020343 |
2019 |
Adult Glioblastoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Mean Ki-67 labeling index was 29% (range, 1.5%-80%). p53 mutation was present in 20/36 GBs (55%), whereas OLIG2 expression was positive in 29/36 GBs (80.5%).
|
31003026 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Specifically, targeting cellular pathways frequently altered in glioblastoma, such as the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), the p53 and the retinoblastoma (RB) pathways, or epidermal growth factor receptor (EGFR) gene amplification or mutation, have failed to improve outcome, likely because of redundant compensatory mechanisms, insufficient target coverage related in part to the blood brain barrier, or poor tolerability and safety.
|
31541850 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Effects of RG7388 and radiotherapy were analyzed in p53 wild-type glioblastoma cell lines and glioma-initiating cells.
|
30274984 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this study, biotinylated PAMAM G3 dendrimers substituted with the recognized anticancer agents cyclooxygenase-2 (COX-2) inhibitor celecoxib and peroxisome proliferator-activated receptor γ (PPARγ) agonist Fmoc-L-Leucine (G3-BCL) were tested in vitro on human cell lines with different p53 status: glioblastoma (U-118 MG), normal fibroblasts (BJ) and immortalized keratinocytes (HaCaT).
|
31652556 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma.
|
31241175 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our recent study indicated that TSN has anti-cancer effect in glioblastoma through induction of estrogen receptor β (ERβ) and p53.
|
29629572 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
To determine whether there is a threshold for the TMZ-induced DNA damage response and exploring the factors regulating the switch between p53 dependent survival and death, the glioblastoma lines LN-229 (deficient in MGMT) and LN-229MGMT (stably transfected with MGMT) were exposed to different doses of TMZ. p53 protein expression and phosphorylation levels of p-p53ser15 and p-p53ser46 were determined by Western blotting.
|
30925722 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Extracellular Vesicles Released by Glioblastoma Cells Stimulate Normal Astrocytes to Acquire a Tumor-Supportive Phenotype Via p53 and MYC Signaling Pathways.
|
30353492 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Correlation analysis of expressions of PTEN and p53 with the value obtained by magnetic resonance spectroscopy and apparent diffusion coefficient in the tumor and the tumor-adjacent area in magnetic resonance imaging for glioblastoma.
|
29745082 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
We used CRN2 knock-out mice for analyses as well as for crossbreeding with a Tp53/Pten knock-out glioblastoma mouse model.
|
31677819 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
We studied the association of immunohistochemical expression of hypoxia inducible factor-1 alpha (HIF-1α), telomerase reverse transcriptase (TERT), isocitrate dehydrogenase 1 (IDH1) and tumor protein p53 with overall survival (OS) in glioblastoma patients uniformly treated by standard of care, with adequate follow-up.
|
31258744 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
|
31081046 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Hairless regulates p53 target genes to exert tumor suppressive functions in glioblastoma.
|
30191601 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRα Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma.
|
30594071 |
2019 |
Adult Glioblastoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Role of asparagine endopeptidase in mediating wild-type p53 inactivation of glioblastoma.
|
31400201 |
2019 |
Adult Glioblastoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The Kaplan-Meier survival plot illustrated poor survival in glioblastoma patients with over-expressed LINC-ROR ( P=0.010) and down-regulated p53 ( P=0.002).
|
30852975 |
2019 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, clear positive effects were seen in a p53 proficient glioblastoma line (U87) when the cells were grown under serum free conditions, while no effects were found in p53 deficient glioblastoma cells (U251).
|
29649215 |
2018 |
Adult Glioblastoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
No difference in overall survival was registered between p53 normally expressed (NE) and overexpressed (OE) glioblastoma patients (P = 0.669).
|
29369420 |
2018 |
Adult Glioblastoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
DNA-damage regulated autophagy modulator 1 (DRAM1) is known as a target of TP53-mediated autophagy, and has been reported to promote the migration and invasion abilities of glioblastoma stem cells.
|
30013633 |
2018 |
Adult Glioblastoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Fifty-two percent of patients diagnosed with glioma/glioblastoma with a positive TP53 mutation had at least one concurrent mutation in a known pathogenic gene of which 9% were CDKN2A, 41% were IDH1, and 11% were PIK3CA.
|
29454261 |
2018 |